Ten large-cap stocks experienced significant declines during the week of February 23-27, 2026. Notable losers include First Solar (down 18.59% due to worse-than-expected Q4 results and below-estimate FY26 guidance), Zoom Communications (down 17.38% following mixed Q4 results and weak forward guidance), and Novo Nordisk (down 6.59% after announcing Chinese trial results and potential price cuts for Ozempic and Wegovy). Other major decliners include Donaldson, TopBuild, Corebridge Financial, Nu Holdings, KKR, Korea Electric Power, and Pure Storage.

PatentVest released an analysis of 1,200+ patent documents across 50 oral small-molecule GLP-1 programs, revealing dramatic disparities in patent defensibility among competitors. With injectable GLP-1s reaching only 5% of eligible patients and clinical efficacy converging around 12-16% weight loss, long-term market dominance will depend on patent portfolio strength rather than clinical performance alone. Major patent cliffs for semaglutide (2031) and tirzepatide (2036) will determine which assets become franchises versus facing generic competition.

Hims & Hers Health stock has declined 70% over the past year due to slowing GLP-1 drug sales after FDA ended shortage declarations and competitors cut prices. Q4 2025 earnings beat on profit but missed on sales, with quarterly growth halving to 28% from full-year 59%. However, management emphasizes that the majority of revenue comes from non-GLP-1 offerings and remains confident in achieving $2.8 billion in 2026 sales.

Eli Lilly strengthened its leading position in the GLP-1 weight loss drug market with two major developments: Novo Nordisk's CagriSema failed to outperform Lilly's Zepbound in clinical trials, and Lilly launched a new convenient monthly-dose pen format for Zepbound. With 60% U.S. market share and a projected $100 billion market over four years, Lilly is well-positioned for continued growth, though competition from Pfizer and Viking Therapeutics remains a potential threat.

Novo Nordisk announced a 50% price cut on its GLP-1 drugs including Ozempic and Wegovy, reducing list prices to $675/month starting in 2027. The company also partnered with Vivtex Corporation for next-generation oral obesity drugs. However, stock declined following disappointing trial data from REDEFINE 4, hitting a 52-week low.

Novo Nordisk and Vivtex Corporation announced a strategic partnership to develop oral biologic medicines for obesity, diabetes, and related conditions. Vivtex will license its proprietary oral drug-delivery technologies to Novo Nordisk, with potential payments up to $2.1 billion plus royalties. The collaboration combines Novo Nordisk's expertise in peptide therapeutics with Vivtex's AI-enabled gastrointestinal screening platform to enable oral delivery of biologic drugs traditionally limited to injection.

While Novo Nordisk is a leader in the GLP-1 drug market with popular products like Wegovy and Ozempic, the article argues the company is unlikely to deliver the 25.89% annual returns needed to turn $100,000 into $1 million over the next decade. The company faces increasing competition from Eli Lilly, its next-gen weight loss drug CagriSema underperformed in trials, and revenue is projected to decline in 2026. However, the stock may still be worth considering as a long-term buy given its diabetes market leadership, deep pipeline, and dividend yield.

Hims & Hers Health (HIMS) has plummeted 75.50% from its May 2025 all-time high of $64.65, largely due to a February 2026 lawsuit from Novo Nordisk alleging unlawful marketing of unapproved semaglutide versions. Despite the sharp decline, analysts remain bullish with an average 12-month price target of $39.32 suggesting nearly 150% upside. The company is expected to report record quarterly revenue of $619 million on February 23, and its oversold RSI reading of 16.87 suggests a potential near-term bullish reversal. Beyond GLP-1 headwinds, Hims' other business segments in telehealth, hair thinning, and sexual health supplements show strong growth prospects.

Novo Nordisk and United Laboratories announced positive phase 2 trial results for UBT251, a triple agonist obesity drug, showing 19.7% body weight loss in Chinese patients. However, the news comes after Novo Nordisk's stock plunged due to disappointing results from its REDEFINE 4 trial, where CagriSema failed to demonstrate non-inferiority against Eli Lilly's tirzepatide.

Viking Therapeutics' weight-loss drug candidate VK2735 has posted strong mid-stage data and is in phase 3 clinical trials, positioning it as a potential disruptor in the rapidly growing obesity drug market. While the stock could deliver outstanding returns if it successfully navigates clinical and regulatory hurdles, investors should be aware of significant risks including potential clinical setbacks and increased market competition.

Novo Nordisk's stock plummeted 16% after its obesity drug CagriSema underperformed in a head-to-head trial against Eli Lilly's tirzepatide, achieving 23% weight loss compared to 25.5%. The setback sent the stock to its lowest point since 2021, with Deutsche Bank downgrading the company from 'Buy' to 'Hold'. Meanwhile, Eli Lilly gained 4.86% as investors reassessed obesity-drug leaders.

Despite a 35% stock decline over the past six months due to competition concerns, Veeva Systems remains a solid long-term buy. The company's specialized cloud services for life sciences companies create strong switching costs and competitive advantages. With a goal to double revenue to $6 billion by 2030 and a history of meeting targets, Veeva is well-positioned to capitalize on the expanding life sciences industry.